NOVARTIS AG SEC Filing
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
IRANNOTICE
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
 |
Novartis AG
P.O. Box
CH 4002 Basel
|
|
US Securities and Exchange
Commission
100 F Street, N.E.
Washington, DC 20549
Basel, February 4, 2026
|
|
|
Re:
|
Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934
|
|
Ladies and
Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human
Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended
December 31, 2025, which was filed with the Securities and Exchange Commission on February 4, 2026.
Respectfully submitted,
Novartis AG
|
|
|
/s/ Karen L. Hale
|
/s/ Harry Kirsch
|
|
|
|
Karen L. Hale
Chief Legal & Compliance Officer of Novartis |
|
Harry Kirsch
Chief Financial Officer of Novartis |
|